Longevity
The latest from Longevity on Vitalspell.
What Life's Essential 8 predicts about living to 100
Life's Essential 8 tracked lower mortality from midlife to centenarians in a 2026 npj Aging study, but it is not a guarantee of living to 100.
Can NMN, NAD+ and resveratrol actually slow aging? Here's what the human evidence says
NMN supplements raise blood NAD+ levels 2.5-fold in human trials, but a 2026 review of 33 studies finds anti-aging benefits remain unproven. Here's what the evidence actually says about the most-hyped longevity compounds.
By day three, fasting changes the whole picture
A seven-day fasting study found the body switches fuels early, but its biggest protein-level changes arrive after day three, with real safety caveats.
A mouse study puts gut particles at the center of aging
A new Aging Cell paper suggests tiny gut-derived exosomes can weaken the intestinal barrier and worsen insulin resistance in mice. The human story is still unwritten.
Cold Plunges and Your Brain: What the Science Actually Shows
Cold plunges trigger a measurable surge of noradrenaline and dopamine, but the RCT evidence for long-term mental health benefits is still thin. Two recent studies clarify what the data do and do not support.
More
Aged garlic compound nudges the fat-brain-muscle axis longevity researchers chase
A new Cell Metabolism paper identifies S-1-propenyl-L-cysteine, a bioactive in aged garlic extract, as an upstream activator of LKB1 that prompts fat tissue to release more eNAMPT. In aged mice, the molecule reduced frailty and improved muscle force. The human data is preliminary.
Longevity supplement NOVOS Core improved vascular aging markers in first human trial
A six-month randomized controlled trial at the University of Surrey found NOVOS Core, a 12-ingredient supplement, improved endothelial function, arterial flexibility, and blood pressure in 61 healthy adults over 40. The effect sizes rival those of structured exercise programs, but the study is modest, single-center, and not yet peer-reviewed.
NMN versus NR: what the 2025 evidence actually says
A 2025 Food Frontiers review compares NMN and NR head to head: both raise blood NAD+, but the human trial record falls short of the longevity-extension claims printed on the supplement box.
Low-dose oral NMN was safe and moved platelet counts in a phase 1/2 ITP trial
A 25-patient phase 1/2 trial published in Nature Medicine found that low-dose oral NMN was well tolerated in adults with steroid-refractory immune thrombocytopenia, with 20 percent meeting the primary platelet-response endpoint and 52 percent maintaining responses through week 8.
NMN and NR supplements: what the evidence says about NAD precursors and aging
NAD levels drop by roughly half between age 40 and 70, and supplement companies are selling NMN and NR as the solution. The human trials show measurable NAD increases but inconsistent clinical benefits, and the regulatory situation for NMN remains unsettled.
Olympic records keep flattening as athletes approach a physiological ceiling
A 2008 paper in PLOS ONE modelled 3,263 world records and forecast that by 2027 half would no longer improve by even 0.05 percent. Sixteen years on, the data have tracked the prediction.
The Vitalspell brief
Evidence-based supplement science — weekly in your inbox.
Subscribe